Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study

Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study - Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011676

Enrollment

200

Registered

2013-09-08

Start date

2013-09-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease

Interventions

Esomeprazole20mg/day1,14days Rabeprazole10mg/day,14days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who have freely given written consent to participating in the study after receiving a full explanation (written and oral) of the study. (2)Patients of either sex who are at least 20 years of age. (3)Patients whose are taking medication of Proton pump inhibitors or Histamine 2 Receptor Antagonists already can be washout of these medications for one week.

Exclusion criteria

Exclusion criteria: (1)Patients with a history of gastrointestinal resection or vagotomy (2)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, bloody disease, cardiac disease or malignant disease. (3)Women who are pregnant or who may possibly be pregnant, and lactating mothers (4)Other patients whom the investigator considers unsuitable for admission to the study

Design outcomes

Primary

Measure	Time frame
Resolution Rate of gastroesophageal reflux disease symptom with each treatment after 2 weeks	—

Secondary

Measure	Time frame
Improvement rate of gastroesophageal reflux disease symptom with each treatment after 2 weeks	—

Countries

Japan

Contacts

Public ContactMotoyasu chibai

Heiwadai clinic Surgery

bk2m-cbi@asahi-net.or.jp03-5922-1241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026